A 20-Second Squeeze Test Predicted Death Better Than Blood Pressure in 139,691 People Across 17 Countries. Every 5 kg of Grip Strength a Man Loses Adds 16 Percent to His Mortality Risk, and It Is Measured in Almost No Physical.
Every physical a man over 40 gets includes a blood pressure cuff, and almost none includes a grip dynamometer, which is odd, because in the largest study ever to compare the two, the dynamometer won. The Prospective Urban Rural Epidemiology study measured grip strength in 139,691 adults across 17 countries on four continents and followed them for a median of four years. Each 5 kg of missing grip strength predicted a 16 percent higher risk of death from any cause and a 17 percent higher risk of cardiovascular death, and the association was stronger than the one for systolic blood pressure. UK Biobank then reproduced the number almost exactly in 502,293 people. The device costs less than a decent pair of running shoes and the test takes 20 seconds per hand. This article covers what grip strength actually measures, how strongly it predicts survival, what a normal number looks like at each age, what testosterone and GLP-1 weight loss do to it, how much of it can be recovered with training at any age, and why the evidence supports it as a marker without supporting it as a cause.
Key Takeaways: What the Grip Strength Evidence Actually Shows
In the PURE study of 139,691 adults aged 35 to 70 in 17 countries, published in The Lancet in 2015, each 5 kg reduction in grip strength was associated with a 16 percent higher risk of all-cause mortality, a 17 percent higher risk of cardiovascular death and a 17 percent higher risk of non-cardiovascular death over a median follow-up of four years, and grip strength predicted death more strongly than systolic blood pressure. In UK Biobank, which measured 502,293 people aged 40 to 69 and followed them for a median of 7.1 years, each 5 kg lower grip was associated with a 16 percent higher all-cause mortality in men and 20 percent in women, and adding grip to a standard office risk score improved prediction of both cardiovascular events and death. Men reach peak grip strength of roughly 51 kg in their thirties, lose about 1 percent a year through their fifties and sixties, and lose 2 to 3 percent a year after 75, crossing the 27 kg sarcopenia threshold set by the European Working Group in their eighties if nothing intervenes. In the Honolulu Heart Program, grip strength measured in 6,089 men aged 45 to 68 predicted disability 25 years later, with the weakest third carrying roughly double the risk of the strongest. GLP-1 weight loss removes lean tissue along with fat, 39 percent of total weight lost in the STEP 1 DXA substudy of semaglutide and about 25 percent in the SURMOUNT-1 substudy of tirzepatide, which makes a falling grip number the earliest practical warning that a man is losing muscle rather than fat. Grip strength is a marker of whole-body muscle and nervous system integrity, not a cause of survival, so training grip in isolation does nothing while whole-body resistance training raises both the number and the thing it measures.
What Each 5 kg of Missing Grip Predicted in 17 Countries
Adjusted hazard ratios per 5 kg lower grip strength from the Prospective Urban Rural Epidemiology study, published by Leong and colleagues in The Lancet in 2015. Grip was measured with a Jamar dynamometer in 139,691 adults aged 35 to 70 across 17 high, middle and low income countries and everyone was followed for a median of four years. The dashed line at 1.0 means no added risk. Each 5 kg decrement carried a 16 percent higher risk of death from any cause and 17 percent higher risk of cardiovascular and non-cardiovascular death, with smaller associations for myocardial infarction and stroke. The model adjusted for age, sex, education, employment, physical activity, tobacco, alcohol and body composition, and the associations held in every income stratum. Grip strength was not associated with new diabetes, respiratory admissions, injurious falls or fractures, which marks it as a predictor of dying rather than of every adverse outcome.
What does grip strength actually measure?
Grip strength measures the maximum force the forearm and hand muscles can produce against a dynamometer, and it serves as a proxy for total body muscle strength, neuromuscular function and general physiological reserve. The standard instrument is a Jamar hydraulic dynamometer, a metal handle with a gauge that reads in kilograms. The Southampton protocol, published by Roberts and colleagues in Age and Ageing in 2011, has the subject seated with the shoulder relaxed, the elbow bent to 90 degrees and the forearm in a neutral position, squeezing as hard as possible for a few seconds, three attempts on each hand, with the highest reading recorded. The whole test takes under a minute. Grip strength correlates with knee extensor strength at roughly 0.5 to 0.7 in older adults, which is why it stands in for leg strength in studies that cannot afford a leg press dynamometer, and it correlates with lean body mass, bone density, nutritional status and inflammatory markers. Bohannon described it in a 2019 review in Clinical Interventions in Aging as an indispensable biomarker for older adults, on the grounds that no other measurement that cheap and that fast predicts as many outcomes. A man with 50 kg of grip in his forties is not being tested on his hands. The test is reading his whole muscular system through the one part of it that fits in a drawer.
How strongly does grip strength predict how long a man lives?
Grip strength predicts all-cause mortality with a hazard ratio of roughly 1.16 to 1.20 per 5 kg lost, which is a larger effect per unit than most conventional risk factors, and the finding has been reproduced across continents, income levels and age groups. The Prospective Urban Rural Epidemiology study, reported by Leong and colleagues in The Lancet in 2015, is the cleanest test because of its breadth. The investigators enrolled 139,691 adults aged 35 to 70 in 17 countries spanning high, middle and low income, measured grip with a Jamar dynamometer at baseline, and followed everyone for a median of four years. After adjustment for age, sex, education, employment, physical activity, tobacco and alcohol use and body composition, each 5 kg decrement in grip strength was associated with a hazard ratio of 1.16 for all-cause mortality, 1.17 for cardiovascular mortality, 1.17 for non-cardiovascular mortality, 1.07 for myocardial infarction and 1.09 for stroke. The associations held in every income stratum. Grip strength was not associated with new diabetes, hospital admission for pneumonia or COPD, injurious falls or fractures, which is worth noting because it means the number is a predictor of dying rather than of every bad outcome. UK Biobank then did the same thing at nearly four times the scale. Celis-Morales and colleagues, writing in the BMJ in 2018, measured grip in 502,293 people aged 40 to 69 and followed them for a median of 7.1 years. Each 5 kg lower grip was associated with a hazard ratio of 1.16 for all-cause mortality in men and 1.20 in women, and with higher mortality from cardiovascular disease, respiratory disease and several cancers. Two cohorts totalling more than 640,000 people, run by different groups on different populations, produced the same number.
Two Cohorts, 640,000 People, One Number
Adjusted hazard ratios for all-cause mortality per 5 kg lower grip strength in the two largest cohorts ever to measure it. PURE, reported in 2015, followed 139,691 people in 17 countries for a median of four years and found 1.16. UK Biobank, reported by Celis-Morales and colleagues in the BMJ in 2018, followed 502,293 people aged 40 to 69 for a median of 7.1 years and found 1.16 in men and 1.20 in women. The two studies were run by different groups on populations with different incomes, ethnicities and healthcare systems, used different follow-up windows, and landed on the same estimate for men. In UK Biobank, adding grip strength to an office-based risk score built from age, sex, smoking, blood pressure, diabetes and body mass index improved the score's ability to predict both cardiovascular events and death.
Is grip strength really a better predictor than blood pressure?
In the PURE study, yes, and the comparison was run inside the same model. Leong and colleagues reported that grip strength was a stronger predictor of both all-cause and cardiovascular mortality than systolic blood pressure, which is the single measurement every physical in the world includes. The two are not competitors in practice, since blood pressure has a proven causal role and decades of trials showing that lowering it saves lives, while grip strength has neither. What the comparison shows is that a cheap functional measurement carries prognostic information the standard panel does not capture. UK Biobank tested that directly. When Celis-Morales and colleagues added grip strength to an office-based risk score built from age, sex, smoking, blood pressure, diabetes and body mass index, the score's ability to discriminate who would die and who would have a cardiovascular event improved. The improvement was modest in absolute terms, as any single addition to a multivariable score tends to be, but it was there, and it was there for a measurement that takes 20 seconds. The American Heart Association made a similar argument for cardiorespiratory fitness in 2016. Grip strength has a weaker mortality gradient than VO2 max at the extremes but it needs no treadmill, no supervising clinician and no 12 minutes of maximal effort, which is why geriatric medicine adopted it years before cardiology adopted fitness testing.
What is a normal grip strength for a man at each age?
A healthy man in his thirties typically produces about 51 kg on a Jamar dynamometer, a man in his sixties about 45 kg, a man in his seventies about 40 kg and a man in his eighties about 33 kg, with wide individual variation around each figure. Those approximate medians come from the largest normative dataset in the English-speaking world, assembled by Dodds and colleagues in PLoS One in 2014 from 12 British studies and 49,964 participants. The pattern is a plateau from the late twenties to the early forties, a slow decline of roughly 1 percent a year through the fifties and sixties, and an acceleration to 2 to 3 percent a year after 75. The shape matches the VO2 max decline curve from the Baltimore Longitudinal Study of Aging almost exactly, which is not a coincidence, since both are reading the same underlying loss of muscle fibre, motor neurons and mitochondrial capacity. The clinical thresholds sit well below the medians. The European Working Group on Sarcopenia in Older People set its 2019 cut-off for probable sarcopenia at 27 kg for men and 16 kg for women. The Foundation for the National Institutes of Health uses 26 kg for men. The Asian Working Group for Sarcopenia uses 28 kg. A man tracking the trend in his own number is doing something more useful than comparing himself to a table. A drop of 5 kg between two annual measurements in a man in his fifties is not normal ageing, which removes about 0.5 kg a year at that stage, and it is exactly the size of decrement the PURE hazard ratios are indexed to.
Where a Man Sits at Each Decade, and Where the Thresholds Are
Approximate median grip strength in kilograms for men by age, drawn from the normative dataset assembled by Dodds and colleagues in PLoS One in 2014 from 12 British studies and 49,964 participants. The curve plateaus from the late twenties to the early forties at about 51 kg, drops roughly 1 percent a year through the fifties and sixties, and accelerates to 2 to 3 percent a year after 75. The dashed lines mark the clinical thresholds for probable sarcopenia: 28 kg from the Asian Working Group, 27 kg from the European Working Group on Sarcopenia in Older People, and 26 kg from the Foundation for the National Institutes of Health. A man on the median trajectory crosses them in his eighties. Individual variation around each median is wide, the values are rounded, and a man's own trend over time carries more information than his position against the curve.
- Approximate median, men
Does midlife grip strength predict what happens in old age?
Yes, and the follow-up that established it ran for a quarter of a century. Rantanen and colleagues, reporting in JAMA in 1999, used the Honolulu Heart Program, which had measured grip strength in 6,089 Japanese-American men aged 45 to 68 between 1965 and 1970, and then assessed the survivors for physical disability 25 years later when they were 71 to 96 years old. Men whose midlife grip strength fell in the lowest third had roughly twice the risk of walking slowly, being unable to rise from a chair without using their arms, and needing help with self-care in old age compared with men in the highest third, after adjustment for age, body mass index, chronic conditions and physical activity. The men were healthy at baseline, which addresses the obvious objection that weak men were already sick. The interpretation the authors offered has held up: strength in midlife sets the reserve that a man draws down through the decades that follow, and a higher starting point delays the moment the reserve runs out. A separate Honolulu analysis by the same group followed the cohort for mortality over 30 years and found that grip strength predicted survival among men who had no chronic disease at baseline, which is the strongest evidence available that the number carries information before illness has had a chance to lower it.
Why would hand strength predict death from heart disease and cancer?
Because grip strength is reading the state of the whole body's muscle, nerve supply, nutrition and inflammatory load, and each of those affects how a man survives a heart attack, a course of chemotherapy or a hospital admission. Skeletal muscle is the largest metabolic organ in the body, the main site of glucose disposal, and the reserve that the body draws on during any serious illness. A man with more muscle handles insulin better, mobilises more amino acids during catabolic stress, gets out of a hospital bed sooner and is less likely to fall. Low grip strength also tracks chronic low-grade inflammation, since interleukin-6 and tumour necrosis factor alpha both accelerate muscle breakdown, and it tracks motor neuron loss, since strength depends on nerve supply as much as on fibre size. The 2018 UK Biobank paper found grip associated with mortality from respiratory disease, chronic obstructive pulmonary disease, and colorectal, lung and breast cancer, which is the pattern one would expect from a measure of how much reserve a person has to survive a serious diagnosis rather than from a measure of any one disease's risk. The PURE null findings point the same way. Grip strength did not predict who would develop diabetes or who would fall and break a bone, but it predicted who would die, which is what a reserve marker should do. Handgrip is not causing anything. It is the gauge on the tank.
Does testosterone raise grip strength?
Modestly, and less than it raises lean mass. Testosterone therapy in older men with low levels reliably increases lean body mass by 1 to 3 kg over a year and reduces fat mass by a similar amount, and it improves lower body strength on leg press and knee extension testing in most trials, but the effect on grip strength specifically has been small and inconsistent. A 2006 meta-analysis by Ottenbacher and colleagues in the Journal of the American Geriatrics Society pooled 11 randomized trials of androgen treatment in older men and found a moderate overall effect on muscle strength that was concentrated in the lower body, with grip contributing little. The Testosterone Trials, which randomized 790 men aged 65 and older with total testosterone below 275 ng per dL to a year of testosterone gel or placebo, reported in the New England Journal of Medicine in 2016 that testosterone improved six-minute walk distance across all participants and increased lean mass, while the physical function gains were smaller than the body composition gains. Testosterone declines roughly 1 percent a year after 30 and grip strength declines at a similar rate, and the two are correlated in cross-sectional studies, but the correlation is weak once age and lean mass are accounted for. The practical reading is that a low grip number is not evidence of low testosterone and a normal testosterone level is not evidence that grip is fine. The two should be measured separately, and a man whose grip is falling while his testosterone is normal has a training and protein problem rather than a hormone problem.
What does GLP-1 weight loss do to grip strength?
No large GLP-1 trial has reported grip strength as an endpoint, but the body composition substudies show that 25 to 40 percent of the weight lost on these medications is lean tissue, and lean tissue is what grip strength measures. In the STEP 1 trial of semaglutide 2.4 mg, published in the New England Journal of Medicine in 2021, a DXA substudy of 140 participants found that lean mass accounted for about 39 percent of total weight lost over 68 weeks. In SURMOUNT-1, the phase 3 trial of tirzepatide, a DXA substudy of 160 participants put the lean fraction at roughly 25 percent. Those proportions are in the same range as conventional diet-induced weight loss, so the medications are not uniquely muscle-wasting, but the absolute amount of muscle lost scales with the absolute weight lost, and these medications remove more weight than any diet. A man who loses 25 kg on tirzepatide with a 25 percent lean fraction has lost about 6 kg of lean tissue, which is a meaningful share of the muscle a man in his fifties carries. The BELIEVE trial of bimagrumab combined with semaglutide, reported in 2025, showed that the lean fraction can be pushed below 10 percent when muscle is actively protected, which demonstrates the loss is preventable rather than inevitable. For a man on a GLP-1 medication, a dynamometer is the cheapest way to tell whether the number on the scale is coming from the right place. A grip number that holds steady while weight falls means the lean loss is being managed. A grip number falling by several kilograms alongside the weight is a signal to raise protein intake and add resistance training before the deficit compounds.
How Much of the Lost Weight Was Muscle
Lean tissue as a percentage of total weight lost, from the DXA body composition substudies of the major GLP-1 trials and two comparators. In the STEP 1 substudy of 140 participants on semaglutide 2.4 mg, lean mass accounted for about 39 percent of the weight lost over 68 weeks. In the SURMOUNT-1 substudy of 160 participants on tirzepatide, the figure was roughly 25 percent, in the same range as conventional dieting. The BELIEVE trial of bimagrumab combined with semaglutide, reported in 2025, drove the lean fraction below 10 percent, shown here as an approximate value, which demonstrates the loss is preventable when muscle is actively protected. None of these trials reported grip strength, but grip tracks lean mass, and the absolute muscle lost scales with the absolute weight lost. A man shedding 25 kg at a 25 percent lean fraction has lost about 6 kg of lean tissue, which a dynamometer will register long before a DXA scan is ordered.
Can strength be rebuilt at any age, and how fast?
Yes, and the study that proved it used nursing home residents with a mean age of 87. Fiatarone and colleagues, reporting in the New England Journal of Medicine in 1994, randomized 100 frail residents aged 72 to 98 to 10 weeks of high-intensity progressive resistance training three times a week, a nutritional supplement, both, or neither. The training group increased muscle strength by 113 percent, gait velocity by 11.8 percent, stair-climbing power by 28.4 percent and thigh muscle cross-sectional area by 2.7 percent. The supplement alone did nothing. The subjects were older than almost anyone reading this and frailer than almost anyone reading this, and their strength more than doubled in under three months. For a man in his forties or fifties the response is faster and larger. Progressive resistance training two to three times a week, working the large muscle groups with loads heavy enough to make the last few repetitions hard, raises strength measurably within four to six weeks and raises grip strength as a by-product, typically by 1 to 3 kg over a few months in previously untrained adults. Training grip in isolation with a spring gripper raises the grip number without raising anything the number stands for, which is the difference between treating the gauge and filling the tank. The mortality evidence for the training itself is separate from the grip evidence and is consistent with it. A 2022 meta-analysis by Momma and colleagues in the British Journal of Sports Medicine pooled 16 prospective studies and found that 30 to 60 minutes a week of muscle-strengthening activity was associated with a 10 to 17 percent lower risk of all-cause mortality, cardiovascular disease and cancer, with the benefit peaking in that range and not increasing beyond it. Protein intake of 1.2 to 1.6 grams per kilogram per day, which is above the standard adult recommendation, supports the muscle response in men over 50 and in anyone losing weight, and creatine monohydrate at 3 to 5 grams a day adds a small further strength gain when combined with training.
Is grip strength causal, or do sick men just squeeze weaker?
Grip strength is a marker rather than a cause, and the evidence supports that reading rather than undermining it. No randomized trial has assigned people to higher grip strength and measured whether fewer of them die, and none ever will, because grip cannot be raised in isolation from the muscle, nerve and metabolic system it reflects. Reverse causation is real. A man with undiagnosed cancer, heart failure or chronic lung disease will squeeze weaker, and some of those men will die within a four-year follow-up for reasons that have nothing to do with muscle. The PURE and UK Biobank investigators adjusted for known disease and the associations survived, and the Honolulu 30-year data found grip predictive in men with no chronic disease at baseline, which is the strongest available defence against the objection. Residual confounding by physical activity, diet and socioeconomic status is harder to eliminate and almost certainly accounts for part of the association. The honest position is that grip strength is one of the best cheap prognostic measurements in medicine and that improving it is only useful insofar as the improvement comes from building the muscle and nervous system it measures. Resistance training does that and has its own mortality evidence. A gripper does not.
How should a man over 40 use this evidence?
Buy or borrow a dynamometer, record the best of three squeezes on each hand once a year, and treat a drop of more than 2 to 3 kg between measurements as a signal that something has changed. A Jamar-style hydraulic dynamometer costs less than a gym membership month and the reading is stable enough to track. Compare the number to the age medians, but weight the trend far more heavily than the absolute value, since a man who starts at 60 kg and falls to 50 has lost more reserve than a man who has sat at 45 for a decade. Add two to three sessions a week of progressive resistance training across the large muscle groups, which is the intervention that raises grip strength and has independent evidence for lower mortality at 30 to 60 minutes a week. Eat 1.2 to 1.6 grams of protein per kilogram of body weight a day. Measure grip before starting any GLP-1 medication and every three months during treatment, since it is the earliest and cheapest signal that lean loss is outrunning fat loss. Do not read a low grip number as a testosterone problem without a blood test, and do not read a normal testosterone level as reassurance about muscle. Grip strength, VO2 max and body composition together give a man a functional picture of his ageing that no blood panel provides, and of the three, grip is the one he can measure in his kitchen.
Strength Doubled at a Mean Age of 87
Percentage change after 10 weeks of high-intensity progressive resistance training three times a week in the trial by Fiatarone and colleagues, published in the New England Journal of Medicine in 1994. The 100 participants were frail nursing home residents aged 72 to 98 with a mean age of 87, randomized to training, a nutritional supplement, both, or neither. The training group increased muscle strength by 113 percent, stair-climbing power by 28.4 percent, gait velocity by 11.8 percent and thigh muscle cross-sectional area by 2.7 percent. The supplement alone changed nothing. The trial remains the clearest demonstration that the muscle and nervous system grip strength reads can be rebuilt at any age, and it is why the practical response to a falling grip number is a barbell rather than a spring gripper. A 2022 meta-analysis of 16 prospective studies found 30 to 60 minutes a week of muscle-strengthening activity associated with 10 to 17 percent lower all-cause mortality.
Frequently Asked Questions
Have more questions? Contact us or explore our full peptide intelligence platform.
Related Articles
Does Telomere Length Determine Lifespan? Short Telomeres Track With Earlier Death. The Genetics Say Longer Ones Raise Cancer Risk.
Does telomere length determine lifespan? Short telomeres track with earlier death, yet genetic studies show longer ones raise the risk of several cancers.
Low-Dose Aspirin Added 8 Percent to Male Mouse Lifespan. In 19,114 Healthy Older Adults, It Added No Healthy Years and Deaths Ran Higher.
Does low-dose aspirin help longevity? It extended male mouse lifespan 8%, but the ASPREE trial in 19,114 healthy older adults found no gain and more bleeding.
Is NAD+ a Peptide? No. It Is a Coenzyme Built From Two Nucleotides, and the Peptide Label Comes From the Clinic, Not the Chemistry
Is NAD+ a peptide? No. NAD+ is a coenzyme built from two nucleotides. What NAD+ is used for, what IV NAD+ studies found, and how it differs from SS-31.